Table 1.

Basic characteristics of study subjects by quartile of IGF-I and IGFBP-3 concentration at study entry

IGF-I (ng/mL)
IGFBP-3 (ng/mL)
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
<110110-131132-159≥160<3,3773,377-3,9363,937-4,421≥4,422
n = 187n = 186n = 183n = 184n = 185n = 185n = 185n = 185
Age (y)*63.7 ± 0.662.4 ± 0.760.3 ± 0.759.0 ± 0.764.5 ± 0.661.5 ± 0.759.0 ± 0.660.2 ± 0.7
Assigned to intervention group (%)40.632.330.128.833.027.033.538.4
Male gender (%)51.972.074.987.082.767.076.858.9
Minority ethnicity (%)10.712.912.010.315.112.410.87.6
Above high school education (%)61.571.073.873.464.969.277.867.6
Current smoker (%)9.113.416.912.515.710.816.88.7
Alcohol (g/d)*8.2 ± 1.18.3 ± 1.011.8 ± 1.46.0 ± 0.98.1 ± 1.07.4 ± 0.99.1 ± 1.39.6 ± 1.3
Current aspirin use (%)23.025.821.920.724.323.821.122.2
Plasma total cholesterol (mg/dl)*198 ± 4.2201 ± 3.4202 ± 3.5199 ± 3.3189 ± 3.7199 ± 2.9197 ± 3.5213 ± 3.6
Serum total carotenoids (μg/dl)*82 ± 4.2102 ± 5.688 ± 3.795 ± 3.783 ± 3.996 ± 5.093 ± 4.795 ± 3.8
Family history of CRC (%)26.726.325.127.726.024.929.725.4
Adenoma in prior 5 y (%)17.726.317.516.322.716.819.518.9
Energy (kcals)*1,876 ± 471,981 ± 442,016 ± 431,962 ± 411,976 ± 471,906 ± 412,045 ± 441,905 ± 42
Vig/moderate activity (h/wk)*12.3 ± 0.9313.1 ± 1.0514.8 ± 1.1013.8 ± 0.9311.7 ± 1.0014.1 ± 1.0314.2 ± 1.0013.9 ± 1.00
BMI (kg/m2)*28.0 ± 0.2927.3 ± 0.2827.6 ± 0.2927.5 ± 0.2727.7 ± 0.2827.4 ± 0.2527.7 ± 0.3027.6 ± 0.28
Waist-to-hip ratio*0.93 ± 0.010.94 ± 0.010.95 ± 0.010.96 ± 0.010.95 ± 0.010.94 ± 0.010.95 ± 0.010.94 ± 0.01
  • Abbreviations: CRC, colorectal cancer; vig/moderate activity, vigorous/ moderate activity.

  • * Values are means ±SE.